{
    "clinical_study": {
        "@rank": "88892", 
        "acronym": "ASET", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "ISIS CRP Rx followed by Placebo"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Placebo followed by ISIS CRP Rx"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether treatment with ISIS CRP Rx can reduce AF\n      (Atrial Fibrillation) burden (percentage of time spent in AF) in subjects with paroxysmal AF"
        }, 
        "brief_title": "Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Paroxysmal Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male of female; age over 18 years\n\n          -  Dual chamber permanent pacemaker implanted\n\n          -  Confirmed diagnosis of paroxysmal atrial fibrillation with an AF burden of 1 to 50%,\n             as derived from pacemaker diagnostic algorithms\n\n          -  Able to have pacemaker antiarrhythmic algorithms turned off for the duration of the\n             study\n\n          -  Able to discontinue all Class I and III antiarrhythmic medication for the duration of\n             the study\n\n          -  Therapeutically anticoagulated with warfarin or dabigatran, and anticipated to be for\n             duration of the study\n\n          -  High sensitivity C-Reactive Protein (hsCRP) between 2 and 10 mg/L (inclusive)\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities in medical history, physical examination, or\n             screening laboratory results that would render a subject unsuitable for inclusion\n\n          -  NYHA class III/IV heart failure\n\n          -  Impaired left ventricular function of less than 45% determined by echocardiography\n             within 3 months of screening\n\n          -  Moderate or greater mitral regurgitation assessed by echocardiography within 3 months\n             of screening\n\n          -  Permanent AF\n\n          -  Continuous Amiodarone therapy within 90 days prior to Study Day 1\n\n          -  Treatment with another Study Drug, biological agent, or device within one-month of\n             screening, or five half-lives of study agent, whichever is longer\n\n          -  Use of systemic corticosteroids or other anti-inflammatory medications including\n             non-steroidal anti-inflammatory drugs (NSAIDs)\n\n          -  Use of statins, ACE inhibitors or AT-receptor antagonists unless on a stable regimen\n             for at least 3 months prior to dosing and will remain on a stable regimen for the\n             duration of the study\n\n          -  Uncontrolled hypertension (BP >160/100)\n\n          -  Current or expected use of any anticoagulant apart from warfarin or dabigatran"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710852", 
            "org_study_id": "ISIS 329993-CS6"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "intervention_name": "ISIS CRP Rx", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Anti-Arrhythmia Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atrial Fibrillation", 
            "Paroxysmal Atrial Fibrillation", 
            "AF"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Eastbourne", 
                    "country": "United Kingdom", 
                    "state": "East Sussex", 
                    "zip": "BN21 2UD"
                }, 
                "name": "Eastbourne General Hospital - Cardiology Department"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients With Paroxysmal Atrial Fibrillation", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Burden measured as percentage of time spent in AF as derived from continuous pacemaker monitoring", 
            "measure": "AF burden reduction", 
            "safety_issue": "No", 
            "time_frame": "113 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "total number of AF episodes\naverage duration of AF per episode\naverage sinus rhythm duration\natrial and ventricular rate during AF episodes", 
                "measure": "To assess the effect of ISIS CRP Rx on the:", 
                "safety_issue": "No", 
                "time_frame": "113 Days"
            }, 
            {
                "measure": "To assess the effect of ISIS CRP Rx on ventricular rate during sinus rhythm", 
                "safety_issue": "No", 
                "time_frame": "113 Days"
            }, 
            {
                "measure": "To assess the effect of ISIS CRP Rx on measures of Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "113 Days"
            }, 
            {
                "description": "Change from Baseline will be compared for each treatment period", 
                "measure": "To assess whether treatment with ISIS CRP Rx reduces hsCRP in subjects with paroxysmal AF", 
                "safety_issue": "No", 
                "time_frame": "113 Days"
            }, 
            {
                "description": "Incidence rates of all Adverse Events will be tabulated by MedRA system Organ Class and by MedRA Term for each treatment group.  Lab Tests, Vital Signs, And ECG Parameters will be summarized by study visit for each treatment group.", 
                "measure": "To assess the safety of ISIS CRP Rx in subjects with paroxysmal AF", 
                "safety_issue": "Yes", 
                "time_frame": "113 Days"
            }, 
            {
                "description": "Incidence rates of all Adverse Events will be tabulated by MedRA system Organ Class and by MedRA Term for each treatment group.  Lab Tests, Vital Signs, And ECG Parameters will be summarized by study visit for each treatment group.", 
                "measure": "To assess the tolerability of ISIS CRP Rx in subjects with paroxysmal AF", 
                "safety_issue": "Yes", 
                "time_frame": "113 Days"
            }, 
            {
                "description": "Trough levels of ISIS CRP Rx will be assessed at intervals throughout the study", 
                "measure": "To assess the pharmacokinetics of ISIS CRP Rx in subjects with paroxysmal AF", 
                "safety_issue": "No", 
                "time_frame": "113 Days"
            }
        ], 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}